SSS

S2MEDICAL AB SER. B

No trades
See on Supercharts
Market capitalization
‪22.23 M‬SEK
−0.3603SEK
‪−22.71 M‬SEK
‪6.97 M‬SEK
Beta (1Y)
1.60

About S2MEDICAL AB SER. B

CEO
Petter Sivlér
Website
Headquarters
Linköping
Founded
2013
ISIN
SE0011725084
FIGI
BBG00MMCBXY8
S2Medical AB engages in research and development in biotechnology. It develops and sells wound healing products for the entire wound healing process focusing on burns and chronic wounds. It offers wound debridement, blood stilling, skin grafting, tissue substitutes, bandage, and antimicrobial products. The company was founded by Petter Sivlér and Mårten Skog on June 13, 2013 and is headquartered in Linköping, Sweden.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of S2M is 0.0839 SEK — it has increased by 7.15% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on OMXSTO exchange S2MEDICAL AB SER. B stocks are traded under the ticker S2M.
S2M stock is 6.67% volatile and has beta coefficient of 1.60. Check out the list of the most volatile stocks — is S2MEDICAL AB SER. B there?
Yes, you can track S2MEDICAL AB SER. B financials in yearly and quarterly reports right on TradingView.
S2M stock has risen by 9.39% compared to the previous week, the month change is a 7.02% rise, over the last year S2MEDICAL AB SER. B has showed a 89.49% decrease.
S2M net income for the last quarter is ‪−3.82 M‬ SEK, while the quarter before that showed ‪−6.06 M‬ SEK of net income which accounts for 36.91% change. Track more S2MEDICAL AB SER. B financial stats to get the full picture.
Today S2MEDICAL AB SER. B has the market capitalization of ‪21.33 M‬, it has decreased by 1.13% over the last week.
No, S2M doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, S2M shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade S2MEDICAL AB SER. B stock right from TradingView charts — choose your broker and connect to your account.
S2M reached its all-time high on Jan 28, 2019 with the price of 70.4852 SEK, and its all-time low was 0.0180 SEK and was reached on Sep 11, 2023.
See other stocks reaching their highest and lowest prices.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So S2MEDICAL AB SER. B technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating S2MEDICAL AB SER. B stock shows the neutral signal. See more of S2MEDICAL AB SER. B technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. S2MEDICAL AB SER. B EBITDA is ‪−14.10 M‬ SEK, and current EBITDA margin is −202.32%. See more stats in S2MEDICAL AB SER. B financial statements.